Marker Therapeutics is a biopharmaceutical company engaged in the discovery and development of immunotherapeutics for the treatment of cancer, infectious diseases, autoimmune disorders, and transplant tissue rejection. The company focuses on conducting studies using its transporters of antigen processing (TAP) gene technology in combination with an adenovirus. Its products include TAP cancer vaccine used for the treatment of breast cancer, prostate cancer, lung cancer, liver cancer, melanoma, renal cancer, and colorectal cancer. Marker Therapeutics was formed as a result of a merger between TapImmune and Marker Therapeutics.